Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep383 | Diabetes (pathiophysiology & epitemiology) | ECE2015

Mechanisms of development of carbohydrate metabolism disturbances in acromegalic patients depending on treatment

Dreval Alexander V , Trigolosova Irina V , Vinogradova Anna V , Wolffenbuttel Bruce H R

Background: In acromegaly, carbohydrate metabolism disorders (CMD) are frequently observed. The effect of therapy of acromegaly on pathogenesis of CMD is not clear.Aim: To assess the effect of somatostatin analogues (SSA) on pathogenesis of carbohydrate metabolism disturbance in acromegaly.Patients and methods: 103 acromegaly patients were examined (31 men, 72 women; age 54 (46–61) years; 60 had newly diagnosed acromegaly (NA)...

ea0037ep927 | Thyroid (non-cancer) | ECE2015

Health-related quality of life is reduced in treated primary hypothyroidism and with lower fT3/fT4-ratio

van Loon Hannah C M , Wouters Hanneke J C M , Kobold Anneke Muller , Slagter Sandra N , Links Thera P , van der Klauw Melanie M , Wolffenbuttel Bruce H R

Introduction: Despite adequate treatment with LT4 monotherapy, many patients with primary hypothyroidism still report complaints, as this treatment can not exactly imitate the endogenous homeostasis. We examined whether the different domains of HR-QOL were affected by the existence of a thyroid disorder and use of LT4 substitution, and whether a lower ratio of free triiodothyronine (fT3)–free thyroxine (fT4)</sup...

ea0041gp152 | Pituitary - Clinical | ECE2016

Effects of hydrocortisone substitution on blood pressure – results from an RCT

Buning Jorien Werumeus , van Faassen Martijn , Brummelman Pauline , Dullaart Robin P F , van den Berg Gerrit , van der Klauw Melanie M , Kerstens Michiel N , Kobold Anneke C Muller , Kema Ido P , Wolffenbuttel Bruce H R , van Beek Andre P

Background: Patients with secondary adrenal insufficiency show increased risk of cardiovascular disease. Higher doses of glucocorticoid replacement are related to an unfavourable metabolic profile. In the absence of randomized controlled trials assessing the effect of hydrocortisone dose on haemodynamics and blood pressure regulation, we determined effects of a higher vs a lower glucocorticoid replacement dose on blood pressure, the renin-angiotensin-aldosterone system (RAAS) ...

ea0037gp.14.01 | Diabetes and obesity – Clinical diabetes | ECE2015

What components drive the metabolic syndrome? Results from the population-based LifeLines Cohort Study

Slagter Sandra N , Waateringe Robert P van , Wendker Marjolein , Vliet-Ostaptchouk Jana V van , Lutgers Helen L , Beek Andre P van , Klauw Melanie M van der , Wolffenbuttel Bruce H R

Background: The metabolic syndrome (MetS) is a combination of unfavourable health factors including visceral obesity, dyslipidaemia, hypertension and impaired fasting glucose. It is also strongly associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes. We assessed which factors contribute to the prevalence of MetS in people within different weight and age categories.Methods: 64 046 western European participants aged 18–80 ...

ea0037gp.20.06 | Pituitary – Hypopituitarism | ECE2015

Somatic complaints, pain and health related quality of life in patients treated for secondary adrenal insufficiency – results from a randomised controlled trial

Buning Jorien Werumeus , Brummelman Pauline , Koerts Janneke , Dullaart Robin P F , van den Berg Gerrit , van der Klauw Melanie M , Tucha Oliver , Wolffenbuttel Bruce H R , van Beek Andre P

Introduction: There is growing evidence that quality of life (QoL) in patients with adrenal insufficiency (AI) is impaired. Undertreatment with glucocorticoids is associated with symptoms such as fatigue and gastrointestinal complaints whereas overtreatment is associated with impaired QoL. However, evidence for this is derived from observational studies which are prone to bias. Therefore, the aim of the present study was to compare two different physiological doses of hydrocor...

ea0037gp.26.09 | Thyroid – hypothyroidism | ECE2015

No effect of Thr92Ala DIO2 polymorphisms on thyroid parameters, health-related quality of life, and cognitive functioning

Wolffenbuttel Bruce H R , van Loon Hannah C M , Elderson Martin F , van Vliet-Ostaptchouk Jana V , Wouters Hanneke J C M , Kobold Anneke Muller , Links Thera P , Slagter Sandra N , van der Klauw Melanie M

Introduction: The Thr92Ala polymorphism of deiodinase 2 (DIO2) is associated with increased expression in the brain of genes associated with oxidative stress, and may predict favourable response to combination thyroxine (L-T4) plus triiodothyronine (T3) therapy. We examined whether the Thr92Ala polymorphism (rs225014) was associated with differences in thyroid hormone parameters, health-related quality of life (HR-QOL) and cognitive functio...

ea0035oc8.5 | Pituitary clinical | ECE2014

The effects of glucocorticoid treatment on cognition in patients with secondary adrenal insufficiency – results from a RCT

Buning Jorien Werumeus , Brummelman Pauline , Koerts Janneke , Dullaart Robin P.F. , van den Berg Gerrit , van der Klauw Melanie M. , Tucha Oliver , Wolffenbuttel Bruce H. R. , van Beek Andre P.

Introduction: A wide variety in hydrocortisone substitution dose-regimens are considered physiological for patients with secondary adrenal insufficiency. However, it is likely that cognition is negatively influenced by higher cortisol exposure to the brain. So far, no studies have been performed to assess the effects of treatment regimens administered for a substantial period of time with a low physiological hydrocortisone dose in comparison to a high physiological hydrocortis...